Young adults with ALL benefit from therapies developed for children

A large, prospective clinical trial adds to mounting evidence that adolescent and young adult patients — aged 16 to 39 with acute lymphoblastic leukemia — fare better when treated with high-intensity pediatric protocols than previous patients treated on adult regimens. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *